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The aim of this study was to develop the valid analytical method which 
used for the assay of triamcinolone acetonide (TA) in the investigation of TA-
loaded nanoparticle formulations. High Performance Liquid Chromatography 
(HPLC) method was applied in this study by using an Econosil column, C18 10 
µm, 250 x 4.6 mm (Alltech Associates Inc, PA, USA) as the stationary phase. 
The mobile phase consisted of a composition of acetonitrile (ACN) and 20mM 
phosphate buffer solution (pH 4.2) in the proportion of 50:50 v/v. The HPLC 
assay of TA was validated for selectivity, linearity, precision, recovery 
(accuracy), sensitivity and stability of TA during the assay. Results showed that 
the concentration of TA in the samples can be determined against the standard 
in the concentration range of calibration curve. The system precision and level of 
recovery were considered to be acceptable, and the method was selective and 
sensitive. 




Tujuan penelitian ini adalah untuk mengembangkan suatu metode 
penetapan kadar triamsinolon asetonida (TA) terkait dengan riset nanopartikel 
TA. Metode HPLC diaplikasikan dengan kolom Econosil sebagai fase diam. 
Sebagai fase gerak, diigunakan komposisi asetonitril: 2 nmM buffer fosfat               
(pH 4.2) dengan perbandingan 50:50. Validasi metode penetapan kadar                 
TA ditetapkan dalam hal selektivitas metode, linearitas respon, ketelitian, 
ketepatan, sensitivitas dan stabilitas TA selama penetapan kadar. Hasil 
menunjukkan bahwa kadar TA dapat ditetapkan dalam rentang kurva baku yang 
dikehendaki. Ketelitian dan ketepatan metode dapat diterima, dan metode 
selektif serta sensitif dalam menetapkan kadar TA pada sampel. 
Kata kunci: triamsinolon asetonida, penetapan kadar, validasi 
 
Introduction  
Recently, Triamcinolone acetonide 
(TA, MW: 434.5) with the structure as 
shown in Figure 1, has been extensively 
investigated in the treatment of a variety of 
ocular diseases associated with inflammation 
and neovascularisation (Jonas et al., 2005; 
Rechtman    et al., 2003; Ciulla     et al., 
2003). The angiostatic effect of TA in 
treating neovascularisation (Obata et al., 
2007), may provide potential for this agent 
to be developed as an antiangiogenesis agent, 
which could be useful in the treatment of a 
range of cancers. 
TA is stable in its solid state, but it is 
unstable in aqueous-alkaline and ethanolic 
solutions.  TA solution is more stable at pH 
values less than 5.5 and minimal degradation 
occurred at pH 3.4 (Gupta, 1982). As TA 
does not ionise, no information on the pKa 
of TA is available.  
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By loading TA into nanoparticles 
(NPs), the nature of TA can be modified, 
leading to the improved delivery of the drug 
to the target site, which is facilitated by                 
a controlled release. Besides, the NPs                    
can protect TA from the unfriendly 
environment (Kreuter, 1994). Although TA 
loaded NPs have been initially investigated 
by Krause (1985), further research is needed 
using other biodegradable polymers and 
potentially superior methods, to improve 
the quality of NPs. To accommodate the 
further TA-loaded NPs  investigation, a 
valid analytical method of determining TA 
needs to be developed.  
Several publications have reported the 
novel HPLC assay for TA (Gupta, 1982; 
Derendorf et al., 1986; Matysova et al., 
2003). A method established by Gupta 
(1982) was adopted in this research with 
some modification since it is stability-
indicating with relatively short retention 
time. 
 
Material and Methods 
Materials 
Micronised TA, batch number: 
2196NMO0100421, chemical grade (Farmabios, 
Italy); Acetonitrile, HPLC grade (LabScan, 
Thailand); Orthophosphoric acid,  Mw 98.00, 
BDH ‘AnalaR’, analytical grade, Min 85 % 
(BDH, Germany); Phosphate Buffer Solution pH 
7.4 preserved by Sodium azide (PBS-NaN3) in 
house production; empty poly-DL-lactide NPs 
(PDLLA-NPs), empty poly(lactic-co-glycolic acid) 
NPs (PLGA-NPs) and empty methoxy-
polyethyleneglycol, poly(D,L, lactic-co-glycolic 
acid) NPs (mPEG-PLGA NPs), all were 
synthesised in house. 
 
Methods 
The TA HPLC method was adopted from 
a reported method (Gupta, 1982) with some 
modification. An Econosil column, C18 10 µm, 
250 x 4.6 mm (Alltech Associates Inc, PA, USA) 
was used as the stationary phase. The mobile 
phase consisted of a composition of acetonitrile 
(ACN) and 20 mM phosphate buffer solution 
(pH 4.2) in the proportion of 50:50 v/v, filtered 
through a 0.45 µm membrane filter prior to use. 
The flow rate of 1.5 mL/min and the injection 
volume of 20 µL were used. The assay validation 
was conducted with TA standards dissolved in 
two media: the ACN:mobile phase 1:1 v/v 
(extracting media) and phosphate buffer              
saline pH 7.4 containing 0.05 % w/v sodium                
azide (PBS-NaN3, release media). To obtain a 
maximum sensitivity, TA was measured at its 
wavelength of maximum absorption: 242 nm. 
The temperature of the system was maintained at 
25 °C. The HPLC assay of TA was validated           
for selectivity, .linearity, precision, recovery 




The peak purity of TA in two different 
media (ACN:mobile phase 1:1 and PBS-NaN3) 
containing TA and degradation products were 
analysed to determine the selectivity of the assay.  
 
Linearity 
Linearity of the assay was determined in 
two types of media for TA loading and release 
study i.e. ACN:mobile phase 1:1 v/v and PBS-
NaN3, respectively. The calibration curve was 
constructed for each type of medium by plotting 




The accuracy of the HPLC assay was 
studied by examining the levels of recovery of 
TA in the presence of empty NPs made of three 
different polymers by the same method used for 
TA loading determination. The recovery was 
calculated by comparing the actual TA 




Figure 1. Structure of triamcinolone 
acetonide (Dollery, 1999). 
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Sensitivity 
Blank solvents were injected six times 
consecutively into the HPLC column and the 
standard deviation of average noise levels in the 
expected retention time were determined. For 
the TA loading determination assay, blank 
solvent was defined as the loading media after 
being filtered from blank NPs, while in the 
release study, blank solvent was the PBS-NaN3. 
The theoretical LOD and LOQ were then 














Stability assay of TA in aqueous environment  
The TA solutions with known 
concentrations were placed in 1.5 mL vials for 
sampling and kept under the experimental 
temperatures.  Samples were taken at 3, 6, 9, 24, 
and 72 hours after initial incubation and 
determined by the HPLC assay. The potency of 







                      
 
Results and Discussion 
To determine the TA concentration, 
an HPLC assay developed by Gupta  (1982) 
was adopted with some modification. 
Selectivity in the HPLC assay development 
was assessed to determine that the peaks can 
be well-separated (Figure 2). The retention 
time of TA and its degradation product in 
release medium (PBS-NaN3), which is 
speculated to be 6β-hydroxyltriamcinolone 
(Sieh, 1982), were approximately 3.7 and 2.9 
minutes respectively, showing that they 
were completely separated (Figure 3.(c)).            
 
 
Figure 2. Purity factor of TA peak on HPLC assay. 
 
 
Table I. Precision of the HPLC method for TA determination 
 
Analytes Average of AUC (mAu*sec) RSD (%) 
1.03 µg/mL of TA solution in ACN: 
mobile phase 1:1 
27.17 1.25 
30.90 µg/mL of TA solution in 
ACN:mobile phase 1:1 
764.33 1.61 
0.53 µg/mL of TA in PBS-NaN3 13.12 0.53 
5.27 µg/mL of TA in PBS-NaN3 130.00 0.08 
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In the release medium, the buffer substances 
and the sodium azide (NaN3, a preservative) 
eluted faster than TA (at 1.6 minutes), 
suggesting that those compounds did not 
interfere with the TA analysis. 
Correlation coefficient r2 was 
calculated for the calibration curve of area 
under the curve (AUC) against the TA 
concentration in both media (Figure 4). The 
detector’s response was found to be linear 
with r2 of 0.9999 and 1 for ACN:mobile 
phase 1:1 media and PBS-NaN3, respectively. 
This suggests that the concentration of TA 
in the samples can be determined against the 
standard in the concentration range of 
calibration curve.   
    
                                a                   b 
   
         c               d 
 
Figure 3. 
(a) Typical HPLC chromatogram of TA standard in ACN:mobile phase 1:1. 
(b) Typical HPLC chromatogram of TA extraction from loaded NPs in ACN: mobile 
phase 1:1. 
(c) Typical HPLC chromatogram of TA (peak 1) and  degradation product (peak 2) in 
PBS-NaN3 at 37 °C over 24 hours. 
(d) Typical HPLC chromatogram of PBS-NaN3 (release medium). 
 
Table II: Recovery of TA in the presence of empty NPs in mobile phase 
 
Parameters Empty PDLLA NPs Empty PLGA NPs Empty mPEG PLGA 
Recovery (%) 99.15 ± 2.79 99.69 ± 1.97 99.91 ± 2.41 
Slope 0.9849 0.9941 0.9921 
Correlation 
coefficient 
0.9999 0.9999 0.9999 
95 % CI slope 0.9738 - 0.9960 0.9813 - 1.0070  0.9798 – 1.0045 
95 % CI Y-
intercept 
-0.5187 to 0.5050 -0.6809 to 0.5036 -0.5961 to 0.5427 
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Precision for the HPLC assay is 
shown in Table I. The relative standard 
deviation (RSD) of the injections was 
obtained below the nominal acceptable level 
of 2 %, indicating that the injection of assay 
was precise for TA analysis. 
The recovery of TA was investigated 
for determination of TA loading to assess 
the interference of the NP matrix in the 
assay. The results are presented in Table II.  
In the presence of empty PDLLA 
NPs, the 95 % confident interval (CI) of the 
slope was 0.9738-0.9960, not including                 
1 (Table II). It indicates that the TA was not 
totally recovered by the assay method in the 
presence of the PDLLA matrix. However, 
the average of recovery was in the                
value of  99.69 ± 1.97 %, with a slope and 
the correlation coefficient of 0.9849 and 
0.9999, respectively. The 95 % CI of Y-
intercept goes through zero, therefore, this 
level of recovery was considered acceptable. 
The recovery levels in the presence of empty 
PLGA NPs and empty 4.8 % mPEG-PLGA 
NPs revealed 95 % CI of slope including              
1 and 95 % CI of Y-intercepts going through 
zero. These data indicate that the assay is 
unbiased and produces a satisfactory 
recovery. The recovery of TA in the           
release media was not carried out since there 
was no extraction method prior to TA 
determination by HPLC in the release 
study.  
In order to assess the sensitivity of the 
assay, the theoretical LOD and LOQ              
were determined both in the loading 
determination and in the release study 
(Table III). 
To determine whether the stability of 
TA in the aqueous environment could be 
maintained during the assay, an investigation 
of the stability of TA in the aqueous 
medium was carried out. In this study, the 
potency of TA in aqueous solutions                
was determined over 72 hours after storage 
at three different experimental temperatures:                
4 °C, 25 °C, and 37 °C.  The data of 
stability study are shown in Figure 5 and 6. 



















   




















                                     a                                                                   b 
Figure 4. Standard curve for TA in ACN:mobile phase 1:1 (a) and  TA in PBS-NaN3 (b). 
 
Table III. LOD/LOQ of the HPLC assay for TA determination 
 
  LOD (µg/mL) LOQ (µg/mL) 
Loading determination: 
- PDLLA NPs 
- PLGA NPs 









Release study: 0.053 0.180 
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TA stability in the extraction medium 
(ACN:mobile phase 1:1 v/v)  was analysed 
using the HPLC assay. The results showed 
that TA degraded slightly faster at higher 
temperatures (Figure 5).  Although Gupta 
(1982) reported that TA is likely to be 
unstable at pH above 5.5 in an aqueous 
medium, a slow process of the degradation 
was also observed in the aqueous medium 
with pH approximately 7.  
The stability of TA in the release 
medium was assessed at 4 °C, 25 °C, and            
37 °C using HPLC assay. To investigate 
whether the stability of TA is affected by 
microbial activity, the study was conducted 
in the release media, with and without                 
a preservative. It was found that the change 
of potency of TA appeared to be 
insignificant affected by the inclusion of 
preservative in the release media over 72 
hours (Figure 6). It may suggest that 
microbial activity does not influence the 
degradation process of TA. 
In the release medium, TA was 
degraded the fastest at 37 °C, as predicted. 
After 72 hours storage at 37 °C, the 
degradation was increased dramatically up to 
43 %. A substantial decomposition of TA 
was found at room temperature, with TA  
potency  reduced to 85 % over 72 hours, 
while at 4 °C the TA showed less than 10 % 
degradation (6.4 %).  
 
Figure 5. Potency of TA over 72 hours. Samples with a known concentration of TA in water 
were kept under experimental temperatures of 4 °C, 25 °C, and 37 °C for 72 hours. 
   
 
 
Figure 6. Potency of TA at 72 hours. Samples with a known concentration of TA in PBS  
and PBS–Na azide (PBS-NaN3) were kept under experimental temperatures 
of 4 °C, 25 °C, and 37 °C for 72 hours.   
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Conclusions 
The assay method of TA showed 
linear response of the detector suggesting 
that the concentration of TA in the            
samples can be determined against the 
standard in the concentration range of 
calibration curve. The precision and                   
level of recovery were considered to be 
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